

# CONTENTS

Preface .....	vii
---------------	-----

## METAL COMPLEXES IN NUTRITION AND METABOLISM

1. Molecular and Biological Properties of Ionophores .....	<b>3</b>
B. C. Pressman, G. Painter, and M. Fahim	
2. Possible Functions and Medical Significance of the Abstruse Trace Metals .....	23
F. H. Nielsen	

## INVOLVEMENT OF METAL COMPLEXES IN DISEASE PROCESSES

3. Metal Carcinogenesis in Tissue Culture Systems .....	45
M. Costa, M. K. Jones, and O. Lindberg	
4. Metal Ion–Nucleic Acid Interactions: Aging and Alzheimer's Disease .....	75
G. L. Eichhorn, J. J. Butzow, P. Clark, H. P. von Hahn, G. Rao, J. M. Heim, E. Tarien, D. R. Crapper, and S. J. Karlik	

## RADIOPHARMACEUTICALS FOR DIAGNOSIS AND TREATMENT

5. Technetium-99m Radiopharmaceuticals: Uses, Problems, Potential Applications in Nuclear Medicine .....	91
L. G. Marzilli, R. F. Dannals, and H. D. Burns	
6. Synthetic and Structural Aspects of Technetium Chemistry as Related to Nuclear Medicine .....	103
E. Deutsch and B. L. Barnett	
7. <b>Radiolabeled</b> Compounds of Biomedical Interest Containing Radioisotopes of Gallium and Indium .....	121
M. J. Welch and S. Moerlein	

## ANTICANCER ACTIVITY OF METAL COMPLEXES

8. Introduction to Metal Complexes and the Treatment of Cancers ...	143
B. Rosenberg	
9. Binding of a Platinum Antitumor Drug to Its Likely Biological Targets .....	147
S. J. Lippard	
10. The Potential of Ruthenium in Anticancer Pharmaceuticals .....	157
M. J. Clarke	
11. Correlations of Physico-Chemical and Biological Properties with in Vivo Biodistribution Data for Platinum-195m-Labeled Chloroammineplatinum(II) Complexes .....	181
J. D. Hoeschele, T. A. Butler, and J. A. Roberts	

12. Structural Studies of the Hydrolysis Products of Platinum Anticancer Drugs, and Their Complexes with DNA Bases . . . . .	209
C. J. L. Lock	
13. The Genetic Toxicology of Substitutionally Inert Transition Metal Complexes . . . . .	227
G. Warren, S. J. Rogers, and E. H. Abbott	
14. The Iron Bleomycins . . . . .	237
J. C. Dabrowiak, F. T. Greenaway, F. S. Santillo, S. T. Crooke, and J. M. Essery	

**CHELATION THERAPY FOR REMOVAL OF IRON OVERLOAD IN COOLEY'S ANEMIA**

15. Iron Chelation in the Treatment of Cooley's Anemia . . . . .	251
W. F. Anderson	
16. High Affinity Iron Transport in Microorganisms: <b>Iron(III)</b> Coordination Compounds of the Siderophores Agrobactin and Parabactin . . . . .	263
J. B. Neilands, T. Peterson, and S. A. Leong	
17. The Design of Chelating Agents for the Treatment of Iron Overload . . . . .	279
C. G. Pitt and A. E. Martell	
18. The Synthesis, Thermodynamic Behavior, and Biological Properties of Metal-Ion-Specific Sequestering Agents for Iron and the Actinides . . . . .	313
K. N. Raymond, W. R. Harris, C. J. Carrano, and F. L. Weil	

**CHELATION THERAPY FOR REMOVAL OF TOXIC OVERLOADS OF OTHER METAL IONS**

19. Chelate Therapy for Type b Metal Ion Poisoning . . . . .	335
M. M. Jones and M. A. Basinger	
20. Gold-Binding to Metallothioneins and Possible Biomedical Implications . . . . .	349
C. F. Shaw III	
21. Wilson's Disease and the Physiological Chemistry of Copper . . . . .	373
I. H. Scheinberg	
22. Computer-Predicted Drugs for <b>Urothaisis</b> Therapy . . . . .	381
M. Rubin, A. E. Martell, R. Gohil, J. C. Penhos, P. Weiss, and R. J. Motekaitis	
Appendix . . . . .	409
Index . . . . .	417